Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Authors :: Jonathan W. Friedberg
Carrie A. Thompson
Marek Trněný
Franck Morschhauser
Gilles Salles
Patrick M. Reagan
Mark Hertzberg
Piotr Smolewski
Huilai Zhang
Catherine Thieblemont
Bei Hu
Gustavo Fonseca
Won-Seog Kim
Maurizio Martelli
Amitkumar Mehta
Avrita Campinha-Bacote
Mark Yan
Jamie Hirata
Matthew Sugidono
Calvin Lee
Jeff P. Sharman
Source :: Blood. 140:6623-6626
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Tools